JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tofovic, S. P.
Right arrow Articles by Jackson, E. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tofovic, S. P.
Right arrow Articles by Jackson, E. K.

Caffeine potentiates vasodilator-induced renin release

SP Tofovic, KR Branch, RD Oliver, WD Magee and EK Jackson

Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee.

Previous studies strongly suggest that adenosine receptors on juxtaglomerular cells function to restrain the secretion of renin induced by a variety of stimuli. The clinical significance of this is that caffeine, a widely consumed adenosine receptor antagonist, could augment renin release responses to diseases such as renovascular hypertension, liver cirrhosis and heart failure and to therapeutic maneuvers such as salt restriction, diuretics and vasodilators. Caffeine may be particularly troublesome in this regard because this methylxanthine has central nervous system effects and intracellular actions that also might contribute to the overall ability of caffeine to potentiate renin secretion. The purpose of this study was to document the effects of caffeine on renin release responses to a vasodilator and to investigate what mechanisms were responsible for any augmentation of vasodilator-induced renin secretion. Accordingly, we compared the effects of caffeine vs. 1,3-dipropyl-8-p- sulfophenylxanthine (DPSPX; a xanthine that we documented in this study not to significantly enter the brain or penetrate cell membranes) on base-line and hydralazine-induced renin release in both normal and beta adrenoceptor-blocked (propranolol, 15 mg/kg) rats. Both xanthines (at a dose of 10 mg/kg plus 150 micrograms/min) attenuated adenosine-mediated hypotension and bradycardia, and DPSPX was at least as effective as caffeine in antagonizing peripheral adenosine receptors. Caffeine and DPSPX increased base-line plasma renin activity to a similar extent regardless of whether the animals were pretreated with propranolol. In rats with an intact beta adrenergic system, caffeine, but not DPSPX, increased the renin release response to low-dose hydralazine (1 mg/kg). Although both xanthines augmented the renin release response to high- dose hydralazine (10 mg/kg), caffeine was more efficacious in this regard. In beta adrenoceptor-blocked rats, neither caffeine nor DPSPX augmented the renin release response to low-dose hydralazine, whereas both xanthines equally potentiated the renin release response to high- dose hydralazine. These data demonstrate that caffeine increases base- line renin release primarily by blocking peripheral (most likely renal), cell-surface adenosine receptors; however, caffeine potentiates vasodilator-induced renin secretion in part by blocking peripheral (most likely renal), cell-surface adenosine receptors and in part by additional central nervous system and/or intracellular mechanism(s) that involve the beta adrenergic system.

Volume 256, Issue 3, pp. 850-860, 03/01/1991
Copyright © 1991 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
E. K. Jackson, J. Ren, L. C. Zacharia, and Z. Mi
Characterization of Renal Ecto-Phosphodiesterase
J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 810 - 815.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. K. Jackson, Z. Mi, L. C. Zacharia, S. P. Tofovic, and R. K. Dubey
The Pancreatohepatorenal cAMP-Adenosine Mechanism
J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 799 - 809.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. K. Jackson, Z. Mi, and R. K. Dubey
The Extracellular cAMP-Adenosine Pathway Significantly Contributes to the in Vivo Production of Adenosine
J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 117 - 123.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
V. Vallon, B. Muhlbauer, and H. Osswald
Adenosine and kidney function.
Physiol Rev, July 1, 2006; 86(3): 901 - 940.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. K. Jackson, L. C. Zacharia, M. Zhang, D. G. Gillespie, C. Zhu, and R. K. Dubey
cAMP-Adenosine Pathway in the Proximal Tubule
J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1219 - 1229.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. K. Jackson, Z. Mi, C. Zhu, and R. K. Dubey
Adenosine Biosynthesis in the Collecting Duct
J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 888 - 896.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
B. Cometti, R. K. Dubey, B. Imthurn, E. K. Jackson, and M. Rosselli
Oviduct Cells Express the Cyclic AMP-Adenosine Pathway
Biol Reprod, September 1, 2003; 69(3): 868 - 875.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
E. K. Jackson and R. K. Dubey
Role of the extracellular cAMP-adenosine pathway in renal physiology
Am J Physiol Renal Physiol, October 1, 2001; 281(4): F597 - F612.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. K. Jackson and Z. Mi
Preglomerular Microcirculation Expresses the cAMP-Adenosine Pathway
J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 23 - 28.
[Abstract] [Full Text]


Home page
HypertensionHome page
R. K. Dubey, D. G. Gillespie, Z. Mi, and E. K. Jackson
Cardiac Fibroblasts Express the cAMP-Adenosine Pathway
Hypertension, September 1, 2000; 36(3): 337 - 342.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. B. Forman, J. V. Vitola, C. E. Velasco, J. J. Murray, R. K. Dubey, and E. K. Jackson
Sustained Reduction in Myocardial Reperfusion Injury with an Adenosine Receptor Antagonist: Possible Role of the Neutrophil Chemoattractant Response
J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 929 - 938.
[Abstract] [Full Text]


Home page
Pharmacol. Rev.Home page
I. Feoktistov and I. Biaggioni
Adenosine A2B Receptors
Pharmacol. Rev., December 1, 1997; 49(4): 381 - 402.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. K. Dubey, Z. Mi, D. G. Gillespie, and E. K. Jackson
Cyclic AMP–Adenosine Pathway Inhibits Vascular Smooth Muscle Cell Growth
Hypertension, November 1, 1996; 28(5): 765 - 771.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1991 by the American Society for Pharmacology and Experimental Therapeutics.